SDF-1 Isoform Quantification via Tandem Mass Spectrometry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack the sensitivity and specificity to accurately quantify endogenous levels of stromal cell-derived factor-1 (SDF-1) isoforms in vivo, particularly in complex biological matrices like plasma and serum, and fail to differentiate intact SDF-1 from its DPP-IV cleaved forms, hindering the study of SDF-1 inactivation suppression by DPP-IV inhibition.
Innovation Solution
A tandem mass spectrometry-based assay that uses immunoaffinity enrichment and stable isotope dilution to quantify SDF-1 isoforms with high sensitivity and sequence specificity, enabling the distinction between intact and NH2-terminal truncated forms, and is capable of detecting SDF-1 at sub-nanomolar concentrations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If mass spectrometry methods are used to measure SDF-1, then sequence specificity is improved, but sensitivity is insufficient for endogenous levels
Solution Approach 1:
The patent employs stable isotope-labeled internal standards as intermediaries to bridge the gap between mass spectrometry measurement and endogenous SDF-1 quantification. These labeled standards serve as detectable proxies that allow the MS system to accurately measure and quantify the otherwise undetectable endogenous levels of SDF-1 isoforms, resolving the sensitivity limitation while preserving sequence specificity
Solution Approach 2:
The invention changes the concentration parameter by spiking samples with known amounts of stable isotope-labeled SDF-1 standards at concentrations above endogenous levels. This parameter change enables the mass spectrometry system to operate in a detectable range while using the known standard concentrations to back-calculate and quantify the endogenous SDF-1 levels, thereby achieving both sensitivity and specificity
2Quantity of substance
If antibody based immunoassays are used to quantify SDF-1, then sensitivity for endogenous levels is improved, but specificity to differentiate isoforms from cleaved forms is lost
Solution Approach 1:
The patent replaces the mechanical/chemical binding mechanism of antibody-antigen recognition with a mass-to-charge ratio based detection mechanism. Instead of relying on antibody specificity that cannot distinguish between intact and cleaved SDF-1, the system uses mass spectrometry to directly measure the molecular mass differences, achieving both sensitivity through signal amplification and specificity through precise mass measurement
Solution Approach 2:
The invention changes the detection parameter from antibody binding affinity to mass-to-charge ratio measurement. By monitoring specific mass transitions in the mass spectrometer, the system can distinguish between intact SDF-1 isoforms and their DPP-IV cleaved forms based on their exact mass differences, thereby achieving specificity that antibody assays cannot provide while maintaining sensitivity through the MS detection method
3Reliability
If DPP-IV inhibition studies are conducted with infused SDF-1, then in vivo suppression effects can be observed, but direct evidence of endogenous SDF-1 inactivation suppression is not obtained
Solution Approach 1:
The patent changes the concentration parameter by using stable isotope-labeled standards spiked at supra-endogenous concentrations to enable detection, while the actual measurement and quantification focus on the endogenous SDF-1 levels present in the sample. This allows the assay to detect and quantify the relatively low endogenous SDF-1 concentrations without being overwhelmed by the detection limit, thereby providing reliable evidence of DPP-IV inhibition effects on endogenous SDF-1
Solution Approach 2:
The invention creates a copy of the endogenous SDF-1 molecules using stable isotope-labeled versions that have identical physical and chemical properties but distinct mass signatures. These labeled copies serve as measurable proxies that allow indirect quantification of the endogenous SDF-1 levels and their response to DPP-IV inhibition, providing reliable evidence without requiring direct measurement of the undetectable endogenous molecules
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The assay achieves absolute quantification of SDF-1 isoforms with a broad linear range, spanning picomolar to nanomolar levels, allowing for the measurement of endogenous SDF-1 in vivo and providing evidence of SDF-1 suppression by DPP-IV inhibition in both animal models and non-human primates.
Implementation Method 1
an intact and NH2 terminus cleaved SDF-1 isoform is enriched from plasma through binding to immobilized antibodies
Implementation Method 2
The assay exhibits a broad linear range (103) with a lower limit of quantification (LLOQ) at low picomolar (pM) level, which is sufficiently lower than the endogenous concentration
Data Source
AI summary
The present invention relates to an assay for determining endogenous levels of analyte in vivo. In particular, the present invention is directed to an assay for determining endogenous levels of stromal cell-derived factor (SDF-1) isoforms in vivo.